Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; com… Read more
Longeveron LLC (LGVN) - Total Assets
Latest total assets as of September 2025: $15.56 Million USD
Based on the latest financial reports, Longeveron LLC (LGVN) holds total assets worth $15.56 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Longeveron LLC - Total Assets Trend (2018–2024)
This chart illustrates how Longeveron LLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Longeveron LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Longeveron LLC's total assets of $15.56 Million consist of 76.8% current assets and 23.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.3% |
| Accounts Receivable | $84.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.40 Million | 9.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Longeveron LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Longeveron LLC's current assets represent 76.8% of total assets in 2024, an increase from 39.6% in 2018.
- Cash Position: Cash and equivalents constituted 75.3% of total assets in 2024, up from 38.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 12.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 9.4% of total assets.
Longeveron LLC Competitors by Total Assets
Key competitors of Longeveron LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Longeveron LLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Longeveron LLC generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Longeveron LLC is currently not profitable relative to its asset base.
Longeveron LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 7.67 | 0.48 |
| Quick Ratio | 2.09 | 7.67 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.40 Million | $ 20.67 Million | $ -1.98 Million |
Longeveron LLC - Advanced Valuation Insights
This section examines the relationship between Longeveron LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.04 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 111.6% |
| Total Assets | $25.56 Million |
| Market Capitalization | $14.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Longeveron LLC's assets below their book value (0.58 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Longeveron LLC's assets grew by 111.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Longeveron LLC (2018–2024)
The table below shows the annual total assets of Longeveron LLC from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.56 Million | +111.61% |
| 2023-12-31 | $12.08 Million | -55.94% |
| 2022-12-31 | $27.41 Million | -35.90% |
| 2021-12-31 | $42.77 Million | +362.84% |
| 2020-12-31 | $9.24 Million | -12.70% |
| 2019-12-31 | $10.58 Million | +0.60% |
| 2018-12-31 | $10.52 Million | -- |